Labcorp's planned spin-off, Fortrea, to host 2023 Investor Day

BURLINGTON, N.C. , June 5, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced Fortrea, the new company to be formed by the planned spin-off of Labcorp's Clinical Development and Commercialization Services business, will host its inaugural Investor Day

AMP: Association for Molecular Pathology (Europe Congress)

Changjun Yue, MD, PhD

Dr. Changjun Yue is board-certified in hematopathology, molecular genetic pathology and anatomic and clinical pathology. He has been working at Labcorp for more than 20 years. Changjun has built resilient pathologist and scientist teams in both Los Angeles and Shanghai. In his current role, he serves as the CAP/CLIA laboratory director for the Los Angeles Anatomic Pathology and Histology Center of Excellence, and has created the global Complete Pathological Response program.

Allan Watkinson, PhD

Dr. Allan Watkinson is a member of Labcorp’s Scientific Affairs team and is responsible for driving strategy and innovation in Biopharmaceutical CMC Services, as well as providing scientific support for clients. He has a BSc in biochemistry (University of Leeds) and a PhD in physiological biochemistry (Imperial College London). This was followed by 10 years of postdoctoral academic experience in research and development at the National Institutes of Health in Bethesda, Maryland, and at the University of Liverpool.

Deepak Thirunavukarasu, PhD

Dr. Deepak Thirunavukarasu is a lead scientist in the genomics department. In his current role, he is responsible for driving development and validation of qPCR, next-generation sequencing and custom genomic assays at Labcorp’s central laboratory in Indianapolis. In this role, Deepak collaborates with clients and internal teams to develop and adopt assays that fulfill client requirements.

Martin Squires

Martin Squires brings over 25 years of experience in analytical chemistry and has previously led the research and development group for Labcorp Biopharmaceutical Chemistry, Manufacturing and Control with expertise in advanced protein characterization.

Janelle Salkowitz-Bokal, MBA, PhD

Dr. Janelle Salkowitz-Bokal joined Labcorp Drug Development’s flow cytometry team as a staff scientist in 2013, after a 23-year-long career in HIV clinical trials, HIV small molecules that blocked integration and HIV vaccines. Janelle began supervising the targeted cell isolation team in 2014 due to her extensive experience in peripheral cell mononuclear cell isolation.

Lucas Rifkin, MD, FCAP

Dr. Lucas Rifkin is a board-certified hematopathologist as well as anatomic and clinical pathologist in the medical affairs department. He has been with Labcorp Drug Development since August 2019. In his current role, Lucas is a senior medical director with management and leadership responsibilities; he serves as the CAP/CLIA laboratory director for the Indianapolis central laboratory location. Additionally, Lucas reviews cases in anatomic pathology, flow cytometry and hematopathology.  

Sriram Ramanan, PhD

Dr. Sriram Ramanan brings more than 12 years of combined preclinical and clinical contract research organization experience across broad therapeutic areas including oncology, immunology and cell/gene therapy. He joined Labcorp Drug Development in 2014.